Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile.
OBJECTIVE
To investigate the effect of the antibiotic release profiles of levofloxacin-loaded polymeric nanoparticles on their antibacterial efficacy against E. coli biofilm cells.


METHODS
Three distinct antibiotic release profiles are produced by encapsulating levofloxacin in PCL and PLGA nanoparticles by nanoprecipitation and emulsification-solvent-evaporation methods. The antibacterial efficacy is examined over six days by time-dependent biofilm susceptibility testing that takes into account the effects of the biofilm age, antibiotic exposure history, and simulated drug removal.


RESULTS
Biofilm cells that survive the initial antibiotic exposure exhibit a higher antibiotic tolerance than fresh biofilm cells, where the lower the initial exposure, the higher the tolerance of the surviving biofilm cells. The lower antibiotic susceptibility of the surviving biofilm cells is transferred to their planktonic cell progeny, which can subsequently form new biofilm colonies having a higher antibiotic tolerance, hence exacerbating the infections. A biphasic extended release profile at an appropriate dose can inhibit the biofilm growth for four days, therefore reducing the dosing frequency. The importance of a high initial antibiotic exposure renders a slow release profile ineffective despite the same dosing amount.


CONCLUSIONS
The antibiotic release profile has an equally significant influence on the biofilm eradication rate as the antibiotic dose.
Cheow
Wean Sin
WS
School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore, 637459, Singapore.
Chang
Matthew Wook
MW
Hadinoto
Kunn
K
D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects*; D004926:Escherichia coli / Q000187:drug effects*; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D053758:Nanoparticles; D015242:Ofloxacin / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin
Antimicrob Agents Chemother. 1992 Jul;36(7):1347-51
1510427
Pharm Res. 2002 Feb;19(2):189-94
11883646
Antimicrob Agents Chemother. 2006 Apr;50(4):1552-4
16569882
Biol Proced Online. 2006;8:194-215
17242736
Lancet. 2004 Aug 14-20;364(9434):613-20
15313363
Eur J Pharm Biopharm. 1999 Nov;48(3):207-15
10612031
Int J Pharm. 2008 Mar 20;352(1-2):317-23
18160236
Pharmacotherapy. 2002 Oct;22(10):1216-25
12389872
J Control Release. 1999 Feb 1;57(2):171-85
9971898
Nanomedicine (Lond). 2009 Jul;4(5):519-30
19572818
Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1711-6
10556145
J Antimicrob Chemother. 2003 Dec;52(6):981-6
14613962
Int J Med Microbiol. 2002 Jul;292(2):107-13
12195733
Antimicrob Agents Chemother. 1991 Sep;35(9):1824-8
1952852
J Antimicrob Chemother. 2008 Apr;61(4):859-68
18305202
Am J Respir Crit Care Med. 2000 Nov;162(5):1905-11
11069833
Antimicrob Agents Chemother. 2007 Oct;51(10):3771-4
17682107
Biomaterials. 2009 May;30(13):2591-7
19176245
Int J Infect Dis. 2002 Jun;6(2):144-6
12146499
Nature. 2005 Aug 25;436(7054):1171-5
16121184
J Pharm Sci. 1994 Apr;83(4):463-7
8046597
Int J Pharm. 2009 May 21;373(1-2):141-6
19429299
Pharm Res. 2009 Aug;26(8):1847-55
19407933
J Pharm Sci. 2008 Nov;97(11):4915-33
18351641
J Bacteriol. 2001 Dec;183(23):6746-51
11698361
Chest. 2008 Oct;134(4):815-823
18842914
J Drug Target. 2006 Sep;14(8):557-66
17043040
Expert Opin Drug Deliv. 2009 Sep;6(9):897-905
19637984
Int J Antimicrob Agents. 2001 May;17(5):351-6
11337220
Int J Antimicrob Agents. 2006 Aug;28(2):114-21
16837169
Int J Pharm. 2003 May 12;257(1-2):181-94
12711173
J Clin Microbiol. 1999 Jun;37(6):1771-6
10325322
Microbiol Immunol. 1994;38(8):615-9
7799834
Nat Rev Drug Discov. 2003 Feb;2(2):114-22
12563302
FEMS Microbiol Lett. 2004 Jan 15;230(1):13-8
14734160
J Clin Microbiol. 2004 May;42(5):1915-22
15131149
J Control Release. 1999 Feb 1;57(2):151-9
9971894
Curr Opin Biotechnol. 2008 Dec;19(6):637-43
19036576
PLoS Genet. 2009 Dec;5(12):e1000760
20011100